41510 Federal Register / Vol. 72, No. 145 / Monday, July 30, 2007 / Notices 

This designation will become 

effective on July 22, 2007, unless 

Congress provides otherwise prior to the 

effective date. After this effective date, 

HHS will publish a notice in the 

Federal Register reporting the addition 

of this class to the SEC or the result of 

any provision by Congress regarding the 

decision by HHS to add the class to the 

SEC. 

FOR FURTHER INFORMATION CONTACT: 

Larry Elliott, Director, Office of 

Compensation Analysis and Support, 

National Institute for Occupational 

Safety and Health (NIOSH), 4676 

Columbia Parkway, MS C–46, 

Cincinnati, OH 45226, Telephone 513–

533–6800 (this is not a toll-free 

number). Information requests can also 

be submitted by e-mail to 

OCAS@CDC.GOV. 

John Howard 

Director, National Institute for Occupational 

Safety and Health. 

[FR Doc. 07–3686 Filed 7–27–07; 8:45 am] 

BILLING CODE 4160–17–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality Notice of Meeting 

In accordance with section 10(d) of 

the Federal Advisory Committee Act (5 

U.S.C., Appendix 2), announcement is 

made of a Health Care Policy and 

Research Special Emphasis Panel (SEP) 

meeting. 

A Special Emphasis Panel is a group 

of experts in fields related to health care 

research who are invited by the Agency 

for Healthcare Research and Quality 

(AHRQ), and agree to be available, to 

conduct on an as needed basis, 

scientific reviews of applications for 

AHRQ support. Individual members of 

the Panel do not attend regularlyscheduled meetings and do not serve for 

fixed terms or a long period of time. 

Rather, they are asked to participate in 

particular review meetings which 

require their type of expertise. 

Substantial segments of the upcoming 

SEP meeting listed below will be closed 

to the public in accordance with the 

Federal Advisory Committee Act, 

section 10(d) of 5 U.S.C., Appendix 2 

and 5 U.S.C. 552b (c)(6). Grant 

applications for the Announcement of 

Availability of Funds for Grants 

regarding Minority Research 

Infrastructure Support Program (M–

RISP) applications are to be reviewed 

and discussed at this meeting. These 

discussions are likely to reveal personal 

information concerning individuals 

associated with the applications. This 

information is exempt from mandatory 

disclosure under the above-cited 

statutes. 

SEP Meeting on: Minority Research 

Infrastructure Support Program (M–

RISP). 

Date: August 23, 2007 (Open on 

August 23 from 2 p.m to 2:15 p.m. and 

closed for the remainder of the meeting). 

Place: John M. Eisenberg Building, 

AHRQ Conference Center, 540 Gaither 

Road, Rockville, Maryland 20850. 

Contact Person: Anyone wishing to 

obtain a roster of members, agenda or 

minutes of the non-confidential portions 

of this meeting should contact Mrs. 

Bonnie Campbell, Committee 

Management Officer, Office of 

Extramural Research, Education and 

Priority Populations, AHRQ, 540 

Gaither Road, Room 2038, Rockville, 

Maryland 20850, Telephone (301) 427- 

1554. 

Agenda items for this meeting are 

subject to change as priorities dictate. 

Dated: July 23, 2007. 

Carolyn M. Clancy, 

Director. 

[FR Doc. 07–3679 Filed 7–27–07; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

Privacy Act of 1974; Retraction of a 

New System of Records 

AGENCY: Department of Health and 

Human Services (HHS), Centers for 

Medicare & Medicaid Services (CMS). 

ACTION: Notice of retraction of a new 

system of records. 

SUMMARY: The Centers for Medicare & 

Medicaid Services CMS inadvertently 

published a new system of records titled 

‘‘Post Acute Care Payment Reform/ 

Continuity of Assessment Report and 

Evaluation Demonstration and 

Evaluation (PAC–CARE)’’ System No. 

09–70–0569 in the Federal Register (FR) 

on Thursday, April 19, 2007 (72 FR 

19711). CMS is withdrawing the notice 

due to comments received that a routine 

use disclosure provision necessary to 

carry out essential parts of the 

demonstration project was inadvertently 

omitted. The notice of a new system of 

records will be republished at a later 

date with the routine use included. 

FOR FURTHER INFORMATION CONTACT: 

Inquiries may be directed to: CMS 

Privacy Officer, Division of Privacy 

Compliance, Enterprise Architecture 

and Strategy Group, Office of 

Information Services, CMS, Room N2–

04–27, 7500 Security Boulevard, 

Baltimore, Maryland 21244–1850. He 

can also be reached at 410–786–5357 or 

by e-mail at walter.stone@cms.hhs.gov. 

Dated: July 18, 2007. 

William Saunders, 

Acting Deputy Director, Office of Information 

Services, Centers for Medicare & Medicaid 

Services. 

[FR Doc. E7–14631 Filed 7–27–07; 8:45 am] 

BILLING CODE 4120–03–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Assuring Radiation Protection; 

Cooperative Agreement; Request for 

Applications: RFA-FDA-CDRH–07–004; 

Catalog of Federal Domestic 

Assistance Number: 93.103 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

I. Funding Opportunity Description 

The Food and Drug Administration 

(FDA) is announcing its intention to 

receive and consider applications for 

the award of a cooperative agreement in 

fiscal year 2007 (FY07) to provide 

support in furtherance of FDA’s 

responsibilities, under section 532 of 

the Federal Food, Drug, and Cosmetic 

Act (21 U.S.C. 360ii), to establish and 

carry out a comprehensive radiation 

control program. An estimated amount 

of support in FY07 will be for up to 

$400,000, with an additional 5 years of 

support, subject to the condition that in 

addition to FDA funds, augmenting 

funds are transferred to FDA from other 

Federal agencies to fully support this 

program. Funds may not be used to fund 

or conduct international activities or 

initiatives. As the lead Federal agency, 

FDA intends to collect funds from all 

other contributing Federal agencies 

through Interagency Agreements and 

fund one award for up to $400,000 in 

total costs (including both direct and 

indirect costs). After the first year, 

additional years of noncompetitive 

support are predicated upon acceptable 

performance during the preceding year 

and the availability of Federal funds. 

The cooperative agreement will allow 

FDA to continue to work with the 

Nuclear Regulatory Commission and its 

predecessor organizations, the 

Environmental Protection Agency and 

the Federal Emergency Management 

Agency, to provide financial support for 

a forum established to foster the 

exchange of ideas and information 

mstockstill on PROD1PC66 with NOTICES